Minghong Bi

机构：Bengbu Medical College, First Affiliated Hospital of Bengbu Medical College

发表论文 40 篇 · 总被引 4200 次 · h-index 15

代表论文

• Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial (2020 · The Lancet Oncology · 被引 704)
• Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study (2021 · Journal of Thoracic Oncology · 被引 153)
• Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (2024 · JAMA Oncology · 被引 63)
• Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study (2022 · Journal of Thoracic Oncology · 被引 31)
• Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial (2021 · Cancer Biology and Medicine · 被引 31)
• Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial (2021 · 癌症：英文版 · 被引 26)